SOUTH SAN FRANCISCO, Calif., April 1, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that the company has been selected to present at the 2013 BioCentury-Thomson Reuters Future Leaders in the Biotech Industry Conference, to be held in New York City on April 5, 2013. KaloBios President and Chief Executive Officer, David W. Pritchard , will provide an overview of KaloBios and the company's three current clinical programs for its proprietary, patient-targeted monoclonal antibody therapeutics.
When: Friday, April 5, 2013, 9:00 am EDT, Presentation Room 311
Where: Millennium Broadway Hotel and Conference Center, New York, NY
To access the live and archived audio webcast of the KaloBios Future Leaders presentation please log on through a link located in the Investors section of the KaloBios Pharmaceuticals website under the Events & Presentations tab: http://ir.kalobios.com/events.cfm.
A replay of the webcast will be available one hour after the conclusion of the live event.
KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer. For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
Joan E. Kureczka
Tel: (415) 821-2413
Mobile: (415) 690-0210
|SOURCE KaloBios Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved